Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor with alternating bortezomib or lenalidomide plus dexamethasone in transplant-ineligible newly diagnosed multiple myeloma (SABLe)
2020-006060-89Phase 2Active
- Sponsor
- University Hospital Odense
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in multiple myeloma (MM), sponsored by University Hospital Odense. Primary endpoint: Overall response rate at end of induction. Started Jan 2021; status: active.
02
Drugs
selinexor
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-006060-89.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-006060-89.